Last reviewed · How we verify
Marie Kristine Jessen, MD — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Isotonic crystalloids | Isotonic crystalloids | marketed | Intravenous fluid / Crystalloid solution | Critical Care / Emergency Medicine / Perioperative Medicine |
Therapeutic area mix
- Critical Care / Emergency Medicine / Perioperative Medicine · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Hospital for Special Surgery, New York · 1 shared drug class
- National Taiwan University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Marie Kristine Jessen, MD:
- Marie Kristine Jessen, MD pipeline updates — RSS
- Marie Kristine Jessen, MD pipeline updates — Atom
- Marie Kristine Jessen, MD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Marie Kristine Jessen, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/marie-kristine-jessen-md. Accessed 2026-05-17.